Center for the Study of Systems Biology, School of Biology, Georgia Institute of Technology, Atlanta, Georgia, USA.
Mol Pharm. 2010 Dec 6;7(6):2324-33. doi: 10.1021/mp1002976. Epub 2010 Nov 8.
Many drug candidates fail in clinical development due to their insufficient selectivity that may cause undesired side effects. Therefore, modern drug discovery is routinely supported by computational techniques, which can identify alternate molecular targets with a significant potential for cross-reactivity. In particular, the development of highly selective kinase inhibitors is complicated by the strong conservation of the ATP-binding site across the kinase family. In this paper, we describe X-React(KIN), a new machine learning approach that extends the modeling and virtual screening of individual protein kinases to a system level in order to construct a cross-reactivity virtual profile for the human kinome. To maximize the coverage of the kinome, X-React(KIN) relies solely on the predicted target structures and employs state-of-the-art modeling techniques. Benchmark tests carried out against available selectivity data from high-throughput kinase profiling experiments demonstrate that, for almost 70% of the inhibitors, their alternate molecular targets can be effectively identified in the human kinome with a high (>0.5) sensitivity at the expense of a relatively low false positive rate (<0.5). Furthermore, in a case study, we demonstrate how X-React(KIN) can support the development of selective inhibitors by optimizing the selection of kinase targets for small-scale counter-screen experiments. The constructed cross-reactivity profiles for the human kinome are freely available to the academic community at http://cssb.biology.gatech.edu/kinomelhm/ .
由于药物候选物的选择性不足,许多药物在临床开发中失败,这可能导致不必要的副作用。因此,现代药物发现通常依赖于计算技术,这些技术可以识别具有交叉反应潜力的替代分子靶标。特别是,高度选择性激酶抑制剂的开发受到激酶家族中 ATP 结合位点强保守性的阻碍。在本文中,我们描述了 X-React(KIN),这是一种新的机器学习方法,它将单个蛋白激酶的建模和虚拟筛选扩展到系统水平,以便构建人类激酶组的交叉反应虚拟图谱。为了最大限度地覆盖激酶组,X-React(KIN)仅依赖于预测的靶标结构,并采用最先进的建模技术。针对高通量激酶分析实验中可用的选择性数据进行的基准测试表明,对于近 70%的抑制剂,可以有效地在人类激酶组中识别其替代分子靶标,其灵敏度 (>0.5) 较高,而假阳性率(<0.5) 相对较低。此外,在一个案例研究中,我们展示了 X-React(KIN)如何通过优化小规模反筛选实验的激酶靶标选择来支持选择性抑制剂的开发。构建的人类激酶组交叉反应图谱可在 http://cssb.biology.gatech.edu/kinomelhm/ 上免费提供给学术界。